



Supernus Pharmaceuticals, Inc.  
Investor Relations Department  
1550 East Gude Drive  
Rockville, MD 20850  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: SUPN**

|               |                             |
|---------------|-----------------------------|
| Last Trade:   | 38.75                       |
| Trade Time:   | 10:00 AM ET<br>Dec 13, 2017 |
| Change:       | 0.60  (+1.573%)             |
| Day Range     | 38.28 - 38.85               |
| 52-Week Range | 22.25 - 50.05               |
| Volume        | 31,065                      |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Supernus Pharmaceuticals extensive expertise in product development has been built over the past 20 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, upon our acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals.

... [\(more\)](#)

## Stock Information



## Press Releases [\[ View all \]](#)

- Nov 8, 2017*  
[Supernus to Present at Three November Healthcare Conferences](#)
- Nov 6, 2017*  
[Supernus Announces Third Quarter 2017 Financial Results](#)
- Oct 24, 2017*  
[Supernus to Host Third Quarter 2017 Earnings Conference Call](#)
- Sep 18, 2017*  
[Supernus Provides Update on SPN-810 Phase III Clinical Trials](#)
- Aug 15, 2017*  
[Supernus Defeats Second Generic Challenger to Oxtellar XR®](#)

## Financials & Filings [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 16, 2017*  
[Annual Report \(10-K\)](#)
- Apr 27, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 9, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 3, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*  
[Quarterly Report \(10-Q\)](#)